Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Feb;54(2):170-182.
doi: 10.1016/j.dld.2021.04.029. Epub 2021 Dec 16.

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO); Members of the guidelines panel; Coordinator; AISF Members; SID Members; SIO Members; Metodologists
Collaborators
Free article
Practice Guideline

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO) et al. Dig Liver Dis. 2022 Feb.
Free article

Erratum in

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato (AISF), the Società Italiana di Diabetologia (SID) and the Società Italiana dell'Obesità (SIO) reviewed current knowledge on NAFLD. The quality of the published evidence is graded, and practical recommendations are made following the rules and the methodology suggested in Italy by the Centro Nazionale per l'Eccellenza delle cure (CNEC) and Istituto Superiore di Sanità (ISS). Whenever possible, recommendations are placed within the context the Italian Healthcare system, with reference to specific experience and local diagnostic and management resources. Level of evidence: Level of evidence of recommendations for each PICO question were reported according to available evidence.

Keywords: Guidelines; NAFLD; NASH.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Giulio Marchesini participated in NAFLD advisory boards of Astra-Zeneca, Pfizer, Gilead, Novartis and received honoraria for conference from Eli Lilly Elisabetta Bugianesi: Consultant for Gilead, BMS, Boeringher, Intercept, Innova, Novo Nordisk Patrizia Burra received personal fees from Biotest, Kedrion and Chiesi Farmaceutici for occasional scientific collaboration Fabio Marra: Abbvie: consultant fees; Allergan: consultant fees; AstraZeneca: consultant fees; Gilead: speaker honoraria, consultant fees; Intercept: speaker honoraria; Menarini: consultant fees; Novartis: consultant fees; Novo Nordisk: consultant fees Luca Miele: Advisory Board, Consultancy, Invited Speaker: Alfa-Sigma, Boehringer-Ingelheim, BMS, Echosens, Galmed, Gilead Sciences, IBSA, Intercept, MEDA, MyGenomics, Merck Sharp & Dohme, Novartis, Pfizer, ProLon, Promethera, Rottapharm-Madaus, Siemens Healthineers, Synageva Anna Alisi: no disclosures Piero Vajro: no disclosures Mario Masarone: Gilead travel grants, invited speech; Abbvie: travel grants, invited speech, advisory boards Salvatore Petta: Advisor and/or Speaker for Abbvie, Gilead, Intercept and Pfyzer Marcello Persico acted as consultant for Abbvie and Gilead Gianluca Svegliati-Baroni: no disclosures Luca Valenti: Speaking: MSD, Gilead, AlfaSigma, AbbVie; Consulting: Gilead, Pfizer, Astra Zeneca, Novo Nordisk, Intercept pharmaceuticals, Diatech Pharmacogenetics, IONIS; Research: Gilead Massimo Federici: no disclosures Francesco Purrello: no disclosures Ferdinando Carlo Sasso has been member of Advisory Boards for Boehringer and for Ely-Lilly and has received fees for scientific consultation and/or lectures by Jansen, Roche Diagnostics, Novo Nordisk, Sanofi, MSD, Astrazeneca Giovanni Targher: no disclosures Luca Busetto: no disclosures Maria Letizia Petroni: no disclosures Ferruccio Santini has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with obesity and related diseases: AstraZeneca, Aegerion Pharmaceuticals, Amryt, BioItalia, Bruno farmaceutici and Novo Nordisk. Calogero Cammà: no disclosures Agostino Colli: no disclosures

Publication types